Literature DB >> 10712652

The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats.

D C Piper1, N Upton, M I Smith, A J Hunter.   

Abstract

Orexin-A is a novel neuropeptide initially isolated from hypothalamic extracts but now known to be present in fibres distributed throughout the rat CNS including many regions associated with sleep-wake regulation. The recognition of a particularly dense innervation of orexinergic nerves in the locus coeruleus, together with the observed increase in firing rate of locus coeruleus neurons following application of orexin-A in vitro, further highlighted a potential involvement of the peptide in modulating the arousal state. The present study was undertaken to determine the effects of intracerebroventricularly (ICV) administered orexin-A on the sleep-wake cycle of conscious rats using electroencephalographic and electromyographic recordings. When administered at the onset of the normal sleep period, orexin-A (1, 10 or 30 microg/rat ICV) produced a dose-dependent increase in the time rats spent awake during the second and third hours after dosing. The enhancement of arousal was accompanied by a marked reduction in paradoxical sleep and deep slow wave sleep at the highest dose. The latency to the first occurrence of paradoxical sleep was also prolonged. This overall profile of increased arousal and decreased paradoxical sleep is consistent with a high rate of firing of locus coeruleus neurons as would be expected to occur following ICV administration of orexin-A. It is concluded that orexin-A may play an important physiological role in regulating the sleep-wake state, a hypothesis considerably strengthened by the recently reported narcoleptic phenotype of prepro-orexin (the precursor for orexin-A) knockout mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712652     DOI: 10.1046/j.1460-9568.2000.00919.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  84 in total

1.  SB-334867-A: the first selective orexin-1 receptor antagonist.

Authors:  D Smart; C Sabido-David; S J Brough; F Jewitt; A Johns; R A Porter; J C Jerman
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons.

Authors:  P Bourgin; S Huitrón-Résendiz; A D Spier; V Fabre; B Morte; J R Criado; J G Sutcliffe; S J Henriksen; L de Lecea
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

3.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

Review 4.  Hypothalamic control of sleep in aging.

Authors:  Asya Rolls
Journal:  Neuromolecular Med       Date:  2012-03-09       Impact factor: 3.843

Review 5.  Hypocretin/orexin involvement in reward and reinforcement.

Authors:  Rodrigo A España
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 6.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

7.  Acute Post-Traumatic Sleep May Define Vulnerability to a Second Traumatic Brain Injury in Mice.

Authors:  Rachel K Rowe; Jordan L Harrison; Helena W Morrison; Vignesh Subbian; Sean M Murphy; Jonathan Lifshitz
Journal:  J Neurotrauma       Date:  2018-12-18       Impact factor: 5.269

Review 8.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

Review 9.  [The neurophysiology of cataplexy].

Authors:  G Mayer
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

10.  Dual orexin actions on dorsal raphe and laterodorsal tegmentum neurons: noisy cation current activation and selective enhancement of Ca2+ transients mediated by L-type calcium channels.

Authors:  K A Kohlmeier; S Watanabe; C J Tyler; S Burlet; C S Leonard
Journal:  J Neurophysiol       Date:  2008-07-30       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.